Cambrex (CBM) Now Covered by William Blair
William Blair started coverage on shares of Cambrex (NYSE:CBM) in a research note issued to investors on Tuesday. The firm set an “outperform” rating on the biotechnology company’s stock.
CBM has been the topic of a number of other reports. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday. Craig Hallum restated a “buy” rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $62.33.
Shares of Cambrex (CBM) opened at $51.65 on Tuesday. The company has a market capitalization of $1,692.96, a price-to-earnings ratio of 17.22, a PEG ratio of 1.25 and a beta of 2.27. Cambrex has a 52 week low of $42.55 and a 52 week high of $62.95.
Institutional investors have recently made changes to their positions in the stock. YorkBridge Wealth Partners LLC raised its stake in Cambrex by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 97 shares during the period. Riverhead Capital Management LLC raised its stake in Cambrex by 90.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after acquiring an additional 1,264 shares during the period. Advisor Group Inc. raised its stake in Cambrex by 29.8% in the 2nd quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 615 shares during the period. Visionary Asset Management Inc. bought a new stake in Cambrex in the 3rd quarter valued at about $201,000. Finally, Trexquant Investment LP bought a new stake in Cambrex in the 3rd quarter valued at about $209,000.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.